FutureWiseResearch: Global Market Research Reports, USA, UK

Overview

Non-Hodgkin Lymphoma Treatment Market Overview:

According to FutureWise analysis the market for non-hodgkin lymphoma treatment is expected to reach US$ 18.91 billion by 2031 at a CAGR of 8.70%.

Non-Hodgkin lymphoma is a cancer that affects the white blood cells. This reduces the immunity of the patient. This type of cancer is severe which has encouraged an extensive research for developing treatment method that are effective and efficient. This has increased the number of investments made for its research, thereby propelling the non-hodgkin lymphoma treatment market growth. Additionally, the rising awareness regarding the disease, bolstered drug pipeline for the disease treatment and improvements in the diagnostic methodologies for detecting lymphoma and the rising occurrence of NHL, thereby propelling the market growth.

As per the American Cancer Society, NHL is prevalent in the United States that covers over 5% of all the cancers. Radiation therapy is used for treating NHL in its earlier stages. Radiation therapy, along with chemotherapy, is used for treating advanced lymphomas and in case of a widespread HNL, palliative radiotherapy is primarily preferred. Furthermore, as per the Leukemia and Lymphoma Society, 2019, over 80,000 new lymphoma cases were registered, out of which over 74,000 were NHL cases. Additionally, it is projected that over 870,000 people in the United are identified with lymphoma. Moreover, strategic collaborations for cancer therapeutics has bolstered the market growth. For example, Amgen Inc., in 2015, partnered with MerckCo. Inc. to bolster a cancer immunotherapy phase 3 study, investigating Blincyto in combination with Keytruda in people with Diffuse Large B-Cell Lymphoma, a more prevalent NHL.

Major players included in the Non-Hodgkin Lymphoma Treatment Market:

Bristol-Myers Squibb Company
Celgene Corporation
MerckCo. Inc.
F. Hoffmann-La Roche Ltd.
Seattle Genetics Inc.
Takeda Pharmaceutical Company Ltd.
Johnson & Johnson
Eli Lilly and Company
Abbott Laboratories

(Note: The list of the major players will be updated with the latest market scenario and trends)

Non-Hodgkin Lymphoma Treatment Market Segmentation:

By Therapy Type

Radiation Therapy
Chemotherapy
Targeted Therapy
Others

By Drug Type

Opdivo
Adcetris
Rituxan
Imbruvica
Revlimid
Keytruda
Other Drugs

By Region

North America
Europe
Asia-Pacific
Latin America
Middle East and Africa

The market is fragmented into therapy type, drug type and region. The therapy type segment is categorised into radiation therapy, chemotherapy, targeted therapy and other therapy types. The radiation therapy segment is predicted to hold the largest non-hodgkin lymphoma treatment market share owing to its rising adoption across the world and this therapy has lesser side effects than chemotherapy. The drug type segment is categorised into Opdivo, Adcetris, Rituxan, Imbruvica, Revlimid, Keytruda and others. The Revlimid segment is predicted to lead the market and this is owing to the increased sales in 2018 with its effectivity in treating cancer.

The Asia Pacific region is predicted to lead the market during the forecast period due to factors like increased access to healthcare facilities and rising occurrence of NHL. As per the research conducted in 2018, it was projected that the rate of incidence of NHL in China was over 7 per 100,000 annually. AS the prevalence of NHL is increasing each year, many key players are heavily investing in developing advanced drug therapies for meeting the increased demand. Furthermore, the government bodies of the region are constantly undertaking initiatives for creating awareness regarding NHL and its treatment which shall augment the market growth.

Competitive Landscape:

Tier 1 players-established companies in the market with a major market share
Tier 2 players
Emerging players which are growing rapidly
New Entrants

FutureWise Key Takeaways:

Growth prospects
SWOT analysis
Key trends
Key data-points affecting market growth

Objectives of the Study:

To provide with an exhaustive analysis on the global Non-Hodgkin Lymphoma Treatment Market By Therapy Type, By Drug Type and By Region
To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
To evaluate and forecast micro-markets and the overall market
To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
The customization Mobility Care offered are free of charge with purchase of any license of the report
You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

1. Market Introduction
- 1. Objectives of the Study
  2. Market Definition
  3. Market Scope
  3.1 . Years Considered for the Study
  3.2 . Market Covered
  4. Currency
  5. Limitations
  6. Stakeholders
2. Research Methodology
- 1. Research Data
  1.1 . Secondary Data
  1.1.1 . Key Data from Secondary Sources
  1.2 . Primary Data
  1.2.1. Key Data from Primary Sources
  2. Market Size Estimation
  3. Market Breakdown and Data Triangulation
  4. Assumptions for the Study
3. Executive Summary
- 1. Market Outlook
  2. Segment Outlook
  3. Competitive Insights
4. Market Variables, Trends and Scope
- 1. Market Lineage Outlook
  2. Penetration and Growth Prospect Mapping
  3. Industry Value Chain Analysis
  4. Cost Analysis Breakdown
  5. Technology Overview
  6. Regulatory Framework on Country Level
  6.1 . Reimbursement Framework
  6.2 . Standards and Compliances
5. Market Overview
- 1. Market Dynamics
  1.1 . Market Driver Analysis
  1.2 . Market Restraint Analysis
  1.3 . Industry Challenges
6. Market Analysis tools
- 1. Industry Analysis - Porter’s
  1.1 . Supplier Power
  1.2 . Buyer Power
  1.3 . Substitution Threat
  1.4 . Threat from new entrants
  1.5 . Competitive Rivalry
  2. Pestel Analysis
  2.1 . Political Landscape
  2.2 . Environmental Landscape
  2.3 . Social landscape
  2.4 . Technology landscape
  2.5 . Legal Landscape
7. Non-Hodgkin Lymphoma Treatment Market, By Therapy Type Historical Analysis and Forecast 2023-2031 (USD million)
- 1. Radiation Therapy
  2. Chemotherapy
  3. Targeted Therapy
  4. Others
8. Non-Hodgkin Lymphoma Treatment Market, By Drug Type Historical Analysis and Forecast 2023-2031 (USD million)
- 1. Opdivo
  2. Adcetris
  3. Rituxan
  4. Imbruvica
  5 . Revlimid
  6 . Keytruda
  7 . Other Drugs
9. North America Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Mn) Analysis By Country, 2017-2022
  2.1. U.S.A
  2.2. Canada
  2.3. Mexico
  2.4 . Rest of North America
  3. Market Size (USD Mn) Forecast for North America 2023-2031
10. Latin America Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Regional Market Trends
  3. Historical Market Size (US$ Mn) Analysis By Country, 2017-2022
  3.1. Brazil
  3.2. Uruguay
  3.3 . Argentina
  3.4. Rest of Latin America
  4. Market Size (US$ Mn) Forecast for Latin America 2023-2031
11. Europe Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (US$ Mn) Analysis By Country, 2017-2022
  2.1. Germany
  2.2. U.K
  2.3. France
  2.4. Italy
  2.5 . Switzerland
  2.6. Spain
  2.7. Russia
  2.8. Poland
  2.9. Rest of Western Europe
  3. Market Size (US$ Mn) Forecast for Europe 2023-2031
12. Asia Pacific Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Mn) Analysis By Country, 2017-2022
  2.1. Japan
  2.2. China
  2.3. Singapore
  2.4. Korea
  2.5. India
  2.6. Australia and New Zealand
  2.7. ASEAN
  2.8. Rest of Asia Pacific
  3. Market Size (US$ Mn) Forecast for Asia Pacific 2023-2031
13. Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Mn) Analysis By Country, 2017-2022
  2.1. UAE
  2.2. South Africa
  2.3. Egypt
  2.4. Saudi Arabia
  2.5. Rest of MEA
  3. Market Size (US$ Mn) Forecast for MEA 2023-2031
14. Market Share Analysis and Competitive Landscape
- 1. Global Landscape - Key Players, Revenue and Presence
  2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
  3. Global Emerging Companies
  4. North America - Market Share Analysis and Key Regional Players
  5. Europe - Market Share Analysis and Key Regional Players
  6. Asia Pacific - Market Share Analysis and Key Regional Players
  7. Global Key Player - Growth Matrix
15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts)
- 1. Bristol-Myers Squibb Company
  1.1. Company Overview (HQ, Business Segments, Employee Strength)
  1.2. Product Portfolio
  1.3. SWOT Analysis
  1.4. Financial Overview
  1.5. Strategic Overview
  2. Celgene Corporation
  2.1. Company Overview (HQ, Business Segments, Employee Strength)
  2.2. Product Portfolio
  2.3. SWOT Analysis
  2.4. Financial Overview
  2.5. Strategic Overview
  3. MerckCo. Inc.
  3.1. Company Overview (HQ, Business Segments, Employee Strength)
  3.2. Product Portfolio
  3.3. SWOT Analysis
  3.4. Financial Overview
  3.5. Strategic Overview
  4. F. Hoffmann-La Roche Ltd.
  4.1. Company Overview (HQ, Business Segments, Employee Strength)
  4.2. Product Portfolio
  4.3. SWOT Analysis
  4.4. Financial Overview
  4.5. Strategic Overview
  5. Seattle Genetics Inc.
  5.1. Company Overview (HQ, Business Segments, Employee Strength)
  5.2. Product Portfolio
  5.3. SWOT Analysis
  5.4. Financial Overview
  5.5. Strategic Overview
  6. Takeda Pharmaceutical Company Ltd.
  6.1. Company Overview (HQ, Business Segments, Employee Strength)
  6.2. Product Portfolio
  6.3. SWOT Analysis
  6.4. Financial Overview
  6.5. Strategic Overview
  7. Johnson & Johnson
  7.1. Company Overview (HQ, Business Segments, Employee Strength)
  7.2. Product Portfolio
  7.3. SWOT Analysis
  7.4. Financial Overview
  7.5. Strategic Overview
  8. Eli Lilly and Company
  8.1. Company Overview (HQ, Business Segments, Employee Strength)
  8.2. Product Portfolio
  8.3. SWOT Analysis
  8.4. Financial Overview
  8.5. Strategic Overview
  9. Abbott Laboratories
  9.1. Company Overview (HQ, Business Segments, Employee Strength)
  9.2. Product Portfolio
  9.3. SWOT Analysis
  9.4. Financial Overview
  9.5. Strategic Overview
  
  15 Impact of COVID-19
  15.1. Positive influence on the healthcare industry
  15.2. The financial disruption of the manufacturing sector
  15.3. Impact of COVID-19 on emerging companies
  15.4. Significant mandates in the healthcare regulations initiated by administrations
  15.5. The overall economic slowdown of the developing and developed nations
16. Pre and Post COVID-19 Impact
- 1. Positive influence on the healthcare industry
  2. The financial disruption of the manufacturing sector
  3. Impact of COVID-19 on emerging companies
  4. Significant mandates in the healthcare regulations initiated by administrations
  5. The overall economic slowdown of the developing and developed nations
17. Competitive Intelligence and Competitive Matrix
- 1 . Competitive Intelligence
  2. Competitive Matrix
18. Major Deals and Strategic Alliances Analysis
- 1. Joint ventures
  2. Mergers and acquisitions
  3. Licensing and partnerships
  4. Technology Collaborations
  5. Strategic Divestments
  6. Market Entry Strategies
19. Relevant Case Studies and Latest News Updates
20. FutureWise SME Key Takeaway Points for Client

Data Pack license: Data Pack license: $1250

Single user license: Single user license: $2850

Multi user license: Multi user license: $3850

Corporate license: Corporate license: $5000

Ask for Discount

Buy Now

Customize This Report

Partner

Report Overview

Table of Contents

List of Tables

List of figures

Overview

Table of Contents

Report Overview

Table of Contents

List of Tables

List of figures

Need Assistance

What you get

What's included

Our Clients